Chrysalis BioTherapeutics
Manufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2200 Market St Ste 609, Galveston, Texas...Phone Number
(409) 497-4083Website
www.chrysbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Chrysalis BioTherapeutics
Chrysalis BioTherapeutics, Inc. is a clinical stage biotechnology company dedicated to developing and commercializing treatments for serious respiratory disorders and acute radiation exposure. Their lead product, TP508, is a natural peptide designed to restore vascular function and activate stem cell populations to accelerate tissue repair. The company targets patients suffering from acute respiratory distress syndrome (ARDS) and aims to mitigate the effects of radiation exposure. Chrysalis is focused on innovative solutions that address urgent clinical needs in the fields of respiratory health and radiation therapy.Explore more
Chrysalis BioTherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Chrysalis BioTherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Chrysalis BioTherapeutics has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Chrysalis BioTherapeutics
Product Launch: Get notified when Chrysalis BioTherapeutics launches new products
Check if Chrysalis BioTherapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Chrysalis BioTherapeutics had a recent Job posting/layoffs
Check out if Chrysalis BioTherapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Chrysalis BioTherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Chrysalis BioTherapeutics recently announced quarterly report
Recommended Actions
Find VP level buyers at Chrysalis BioTherapeutics
Find 3 more new buyers
Compare Similar Companies to Chrysalis BioTherapeutics
Compare insights from companies similar to Chrysalis BioTherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Chrysalis BioTherapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Chrysalis BioTherapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Chrysalis BioTherapeutics.
Chrysalis BioTherapeutics Tech Stack
A closer look at the technologies used by Chrysalis BioTherapeutics
Chrysalis BioTherapeutics News & Media
Chrysalis BioTherapeutics Selected to Present at Respiratory Innovation Summit
GALVESTON, Texas--(BUSINESS WIRE)--Chrysalis BioTherapeutics today announced it was selected to participate in the 2024 Respiratory Innovation Summit (RIS) at the American Thoracic Society Meeting in San Diego. The Respiratory Innovation Summit (RIS) has been established by the American Thoracic Society to unite innovators, investors, clinicians, and advocacy groups to help create powerful new treatments for deadly and crippling diseases of the lungs and airways. Each year, companies developingChrysalis Receives FDA Approval to Initiate Clinical Trials with Chrysalin™ (TP508)
GALVESTON, Texas--(BUSINESS WIRE)--Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug Administration (FDA) has given the company permission to initiate human clinical trials aimed at treating acute lung failure. With approval of its Investigational New Drug (IND) Application, Chrysalis plans to initiate a Phase 1, Safety and Pharmacokinetic (PK) study for use of Chrysalin™ (Rusalatide Acetate, TP508) as an injectable drug by year-end and testing of the drug in patients wiChrysalis BioTherapeutics Receives $10.4 Million From BARDA to Continue Development of TP508 as a Nuclear Countermeasure
GALVESTON, Texas--(BUSINESS WIRE)--Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company focused on the development of regenerative medicines to save lives, announced today that the Biomedical Advanced Research and Development Authority (BARDA) part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services executed options to add $10.4 million under contract # HHSO100201900016C with the Company to deveChrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development
GALVESTON, Texas--(BUSINESS WIRE)--Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs that target vascular endothelial and progenitor cells, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has provided additional funding in the amount of $587,995 to its contract with Chrysalis, bringing the total contract award to develop TP508 as a therapeutic for COVID-19
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Chrysalis BioTherapeutics
Sign Up For FreeTo access detailed company insights
Chrysalis BioTherapeutics, Inc. is a clinical stage biotechnology company dedicated to developing and commercializing treatments for serious respiratory disorders and acute radiation exposure. Their lead product, TP508, is a natural peptide designed to restore vascular function and activate stem cell populations to accelerate tissue repair. The com... Read More
